Back

Cardiac damage and 1-year clinical outcomes after transcatheter aortic valve implantation: substudy of the LANDMARK trial

19 February 2026 (08:00 - 18:30)
Organised by: Logo
Congress Presentation Part of: Predicting outcomes after TAVI procedures Intervention EAPCI Premium Access EAPCI Summit 2026 European Association of Percutaneous Cardiovascular Interventions (EAPCI)

About the speaker

Photo
Doctor Akihiro Tobe

University of Galway, Galway (Ireland)

5 More presentations in this session

Presentation thumbnail
Natriuretic peptide dynamics predict long-term outcomes after TAVI
Doctor F. Wenzl (Zurich, CH)
Abstract Slides
Presentation thumbnail
Prevalence and implications of hyponatremia in patients undergoing transcatheter aortic valve replacement
Doctor B. Cohen (Bethlehem, US)
Abstract Slides
Presentation thumbnail
Prognostic impact of supranormal ejection fraction in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation
Doctor M. Immobile Molaro (Naples, IT)
Abstract Slides
Presentation thumbnail
Early reverse remodeling assessed by myocardial work indices and atrial strain following myval transcatheter aortic valve implantation: a prospective single-center study
Doctor G. Papadopoulos (Thessaloniki, GR)
Abstract Slides
Presentation thumbnail
Long-term clinical outcomes after TAVR in patients with oncological disease
Doctor A. Laduss (Riga, LV)
Abstract Slides

Access the full session

Session thumbnail
Predicting outcomes after TAVI procedures

The Event

Event poster

EAPCI Summit 2026

19 February - 20 February 2026

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources